Home / Top News / NGM Bio to Present at Upcoming Investor Conferences

NGM Bio to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present at two upcoming conferences focused on drug research and development for non-alcoholic steatohepatitis (NASH). NGM’s lead clinical candidate, aldafermin (formerly known as NGM282), is currently in Phase 2b clinical development for the treatment of NASH.  Presentation details are as follows:

Monday, October 21, 2019
Event:  H.C. Wainwright 3rd Annual NASH Investor Conference
Location:  New York, NY
Presenter:  David J. Woodhouse, Ph.D., Chief Executive Officer, NGM
Time:  2:00 – 2:20 pm ET

A live webcast of this presentation will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 30 days following the event.

Thursday, October 24, 2019
Event:  B. Riley FBR, Inc.’s NASH Symposium
Location:  San Francisco, CA
Presenters:  David J. Woodhouse, Ph.D., Chief Executive Officer and Aetna Wun Trombley, Ph.D., President and Chief Operating Officer, NGM; Panel Moderator:  Stephen A. Harrison, M.D., Medical Director at Pinnacle Clinical Research, Visiting Professor of Hepatology at University of Oxford, UK
Time:  11:15 – 11:50 am PT

About NGM Biopharmaceuticals, Inc.

NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company leverages its biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable it to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit http://www.ngmbio.com for more information.

Investor Contact:

Sylvia Wheeler and Alex Santos
[email protected]
[email protected]

Media Contact:

Liz Melone
[email protected]


GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.